[TPS in prostate cancer].
A study of the tumour proliferation marker TPS in prostate cancer has been carried out. The levels of this marker were determined in the following groups: controls (n = 51), prostate hyperplasia (n = 17), prostate cancer in clinical remission (n = 15), and progressive prostate cancer (n = 13). An upper normal limit of 129 U/l (percentile 95) was established. When the progressive disease group was compared with the other groups, a significant difference (p < 0.001) was found. Sensitivity, specificity and positive predictive value obtained in order to dismiss progression were 71%, 94% and 62% respectively.
Rodríguez-Rubio
F I
FI
Departamento de Urología, Facultad de Medicina, Universidad de Navarra, Pamplona.
Monreal
I
I
Robles
J E
JE
Martín-Marquina
A
A
Abad
J I
JI
Rosell
D
D
Zudaire
J J
JJ
Berián
J M
JM
D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000097:blood*; D011237:Predictive Value of Tests; D011470:Prostatic Hyperplasia / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood*; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D010455:Peptides; C089984:tissue polypeptide specific antigen